Takeda (TSE:4502/NYSE:TAK) today announced that it has entered into a license and collaboration agreement with Innovent Biologics (HKEX: 01801) for the development, manufacturing and commercialization ...
Background The development of non-sputum-based tests is an urgent priority to increase access to tuberculosis (TB) diagnostic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback